FourThought Financial Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

FourThought Financial Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$234K	Sell	472 -238	-34%	-$105K	0.02%	339
2026 Q1	$317K	Sell	710 -38	-5%	-$17.7K	0.03%	254
2025 Q4	$339K	Buy	748 +18	+2%	+$7.76K	0.03%	287
2025 Q3	$286K	Buy	730 +19	+3%	+$7.94K	0.03%	375
2025 Q2	$317K	Buy	711 +50	+8%	+$23K	0.03%	230
2025 Q1	$320K	Sell	661 -31	-4%	-$14.4K	0.03%	233
2024 Q4	$279K	Buy	+692	New	+$321K	0.03%	251
2024 Q2	–	Sell	-1,299	Closed	-$543K	–	320
2024 Q1	$543K	Buy	1,299 +5	+0.4%	+$2.11K	0.06%	191
2023 Q4	$527K	Hold	1,294	–	–	0.07%	194
2023 Q3	$450K	Sell	1,294 -53	-4%	-$18.5K	0.06%	197
2023 Q2	$474K	Sell	1,347 -122	-8%	-$41.1K	0.06%	195
2023 Q1	$463K	Sell	1,469 -201	-12%	-$60.3K	0.06%	193
2022 Q4	$482K	Buy	+1,670	New	+$509K	0.07%	189

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

FourThought Financial Partners's VRTX Position: Q2 2026 in Review

FourThought Financial Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 34% in Q2 2026, selling an estimated $105K and leaving 472 shares worth $234K. The position accounts for 0.02% of the portfolio, ranked #339.

FourThought Financial Partners first reported a position in VRTX in Q4 2022 and has held it in 13 quarters since. The position peaked at $543K in Q1 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

FourThought Financial Partners held 472 shares of Vertex Pharmaceuticals worth $234K as of Q2 2026.
FourThought Financial Partners sold 238 Vertex Pharmaceuticals shares in Q2 2026, an estimated $105K.
Vertex Pharmaceuticals made up 0.02% of FourThought Financial Partners's portfolio in Q2 2026, its #339 holding.
FourThought Financial Partners first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
FourThought Financial Partners's Vertex Pharmaceuticals position peaked at $543K in Q1 2024.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on FourThought Financial Partners's 13F filing for Q2 2026, filed 12 Aug 2026.